The disconnect between Intuitive Surgical’s operational performance and its stock price has rarely been wider. The robotic surgery pioneer reported a second-quarter earnings beat on July 16, yet its shares have been sliding ever since, closing Tuesday at €306.80 — a stone’s throw from the €299.60 52-week low touched just a day earlier. That puts the stock roughly 40% below its January peak of €516.50 and down 37.28% year-to-date.
The sell-off has been swift: a 9.54% drop in just seven trading sessions. But beneath the surface, a more nuanced picture emerges — one that separates the company’s long-term trajectory from the short-term headwinds currently weighing on sentiment.
The Numbers That Beat, But Didn’t Convince
On paper, Intuitive Surgical delivered a robust quarter. Revenue climbed 19% year-over-year to $2.89 billion, while adjusted earnings per share of $2.80 handily beat the $2.51 consensus estimate. The company installed 468 da Vinci systems during the quarter, up from 395 a year earlier, with 246 of those already being the next-generation da Vinci 5 platform. The global installed base now stands at 11,710 units, a 12% increase.
Yet investors fixated on the fine print. US da Vinci procedure growth decelerated to 12% in Q2, down from 14% in the first quarter. The Ion platform’s growth clocked in at 21%. Management pointed to two specific drags: the expiration of enhanced insurance subsidies under the Affordable Care Act, which had a “moderate negative effect” on procedure volumes, and a decline in bariatric surgeries tied to the rising popularity of GLP-1 weight-loss drugs.
Analysts Cut Targets, But Not Conviction
The post-earnings reaction triggered a wave of price-target reductions across Wall Street, though notably not a single downgrade. Leerink’s Mike Kratky slashed his target from $573 to $454 while maintaining “Outperform.” Citi went from $590 to $500, keeping “Buy.” BofA trimmed to $470 from $515, Raymond James to $483 from $577, and Stifel made the deepest cut — from $670 to $550. TD Cowen lowered to $485 from $520, while RBC Capital made only a modest adjustment to $575 from $600.
BMO Capital, meanwhile, reaffirmed its “Outperform” rating and $518 target on Monday, characterizing the US procedure slowdown as temporary and driven by shifting insurance coverage and expiring subsidies among specific payers — not a fundamental demand problem for robotic surgery.
The analyst community is effectively signaling that the growth story remains intact, but near-term expectations need recalibration. The gap between these still-optimistic targets and the current share price is unusually wide.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
A Valuation Reset of Historic Proportions
The stock now trades at roughly 33 times forward earnings — a far cry from the 70-plus multiple it commanded at various points in its history. For a company that has weathered eight separate drawdowns of 30% or more since its IPO, this latest correction follows a familiar pattern. But the current valuation represents a multi-year low for a growth stock that has rarely been this cheap.
The technical picture reinforces the bearish mood. The 14-day relative strength index sits at 33.1, approaching oversold territory, while the 30-day annualized volatility of 54% underscores the turbulence since earnings. The €300 level is emerging as a potential support zone that traders are watching closely.
The Real Story: Recurring Revenue and Platform Expansion
What gets lost in the noise around quarterly procedure growth is the structural transformation of Intuitive Surgical’s business model. Roughly 85% of revenue now comes from recurring sources — instruments, accessories, and service agreements tied to the expanding fleet of installed systems. That installed base grew 12% year-over-year to 11,710 units, with da Vinci 5 accounting for more than half of new placements in the quarter.
The company maintained its 2026 procedure growth guidance of 13.5% to 15.5%. For some analysts, the failure to raise that range — despite the Q2 beat — was the true catalyst for the sell-off. In a market hungry for good news, the absence of an upgrade was interpreted as a disappointment.
Management is also pushing ahead with the global rollout of both the Ion and da Vinci 5 platforms, with over 100 planned software updates designed to enhance surgeon experience and clinical outcomes. The long-term thesis — that robotic-assisted surgery will continue to gain share from traditional minimally invasive and open procedures — remains unchanged.
The question now is whether the US procedure deceleration proves to be the temporary blip that BMO and others believe, or the beginning of a more sustained slowdown. For a stock trading at a 40% discount to its January high and a fraction of its historical valuation multiple, the market is clearly betting on the former — but demanding proof before it re-rates the shares higher.
Ad
Intuitive Surgical Stock: Buy or Sell?! New Intuitive Surgical Analysis from July 22 delivers the answer:
The latest Intuitive Surgical figures speak for themselves: Urgent action needed for Intuitive Surgical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 22.
Intuitive Surgical: Buy or sell? Read more here...
